Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
Serial carcinoembryonic antigen (CEA) assays were conducted in patients with endocrine-unresponsive prostatic adenocarcinoma who were being treated with multidrug chemotherapy. Changes in CEA correlated with the clinical status of the patient in 70 per cent of the determinations and were more accurate than acid phosphatase in monitoring the response to treatment.
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D011241:Prednisone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology*; D014750:Vincristine / Q000627:therapeutic use
D002272:Carcinoembryonic Antigen; D014750:Vincristine; D000135:Acid Phosphatase; D008558:Melphalan; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate